3/20
04:40 am
ibio
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3 [Yahoo! Finance]
Low
Report
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3 [Yahoo! Finance]
3/18
08:40 am
ibio
iBio (IBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.
High
Report
iBio (IBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.
3/16
05:04 pm
ibio
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) [Yahoo! Finance]
Low
Report
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) [Yahoo! Finance]
3/16
04:30 pm
ibio
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Low
Report
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
3/9
07:03 am
ibio
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss [Yahoo! Finance]
Low
Report
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss [Yahoo! Finance]
3/9
07:00 am
ibio
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
Low
Report
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
3/4
05:51 am
ibio
iBio (IBIO) was upgraded by JonesTrading to "strong-buy".
Medium
Report
iBio (IBIO) was upgraded by JonesTrading to "strong-buy".
3/3
08:27 am
ibio
iBio (IBIO) is now covered by JonesTrading. They set a "buy" rating and a $7.00 price target on the stock.
Low
Report
iBio (IBIO) is now covered by JonesTrading. They set a "buy" rating and a $7.00 price target on the stock.
2/24
07:00 am
ibio
iBio to Participate in Upcoming Investor Conferences
Low
Report
iBio to Participate in Upcoming Investor Conferences
2/12
08:14 am
ibio
iBio (NYSE:IBIO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Medium
Report
iBio (NYSE:IBIO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
2/10
04:05 pm
ibio
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
Low
Report
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
1/9
07:00 am
ibio
iBio Announces $26 Million Private Placement
Medium
Report
iBio Announces $26 Million Private Placement